Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of View Full Study BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions
Improved lipid markers: clinical trials have shown reductions in triglycerides and improvements in HDL/LDL ratios in patients on tesamorelin therapy
Tendon & ligament fibroblast cultures outgrowth rate, collagen organization, receptor expression
The standard AOD 9604 dosage in clinical use is 250500 mcg, administered subcutaneously once every morning on an empty stomach, and cycled in 412-week blocks
When GLP-1 is released it stimulates insulin secretion, reduces glucagon release, and slows gastric emptying
These injections have been shown to boost energy, enhance mood, increase fat metabolism, improve sleep, strengthen and improve quality of hair and nails, as well as the skin